NCT07774299尚未招募2 期
A Multicenter, Single-Arm Clinical Study of Pirtobrutinib Combined With Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preconditioning Regimen for ASCT in Relapsed and Refractory DLBCL
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 28
- 主要终点
- Progression-free survival
研究概览
简要总结
This trial is a prospective, multi-center, single-arm clinical research. The intention is to evaluate the efficacy and safety of pirtobrutinib combined with BEAM as a pretreatment regimen for ASCT in relapsed and refractory DLBCL patients.
详细描述
A total of 28 patients with relapsed/refractory DLBCL are planned to be enrolled in this trial. They will receive pirtobrutinib in combination with the BEAM regimen as conditioning therapy, followed by ASCT. The study comprises a screening period, a treatment period (days -8 to -2, 7 days in total), and a 2-year follow-up period after transplantation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •According to world Health Organization (WHO) classification of disease, diffuse large B-cell lymphoma was confirmed by histology, CR or PR after second-line and above treatment;
- •18≤ age ≤70 years old, male or female;
- •ECOG score 0-2;
- •No serious organic lesions in the main organs, meeting the requirements of the following laboratory examination indicators (conducted within 7 days before treatment) :
- •White blood cell count ≥3.0×109/L, absolute neutrophil count ≥1.5×109/L, Hemoglobin ≥90g/L, platelet ≥75×109/L;
- •Total bilirubin ≤1.5× upper normal value (ULN);
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5× ULN; Bilirubin ≤1.5× ULN
- •Creatinine clearance was 44-133 mmol/L;
- •No cardiac dysfunction;
- •Life expectancy over 3 months;
- •The subject or his/her legal representative must provide written informed consent prior to conducting a special study examination or procedure.
排除标准
- •Previously received autologous hematopoietic stem cell transplantation;
- •Suffering from serious complications or severe infection;
- •Central nervous system lymphoma was excluded;
- •A history of other malignant tumors within 5 years, excluding early tumors treated for curative purposes;
- •Patients with uncontrolled cardiovascular and cerebrovascular diseases, coagulation disorders, connective tissue diseases, serious infectious diseases, etc.;
- •HBsAg, HCV or HIV positive. Positive HBV and HCV serology is allowed, but DNA/RNA testing must be negative;
- •Left ventricular ejection fraction ≦ 50%;
- •Laboratory test value during screening;
- •① Neutrophils <1.5×109/L; Platelet <75×109/L;
- •② Bilirubin was 1.5 times higher than the normal upper limit, transaminase was 2.5 times higher than the normal upper limit;
- •③ The creatinine level is higher than 1.5 times the upper limit of normal value;
- •Other concurrent and uncontrolled medical conditions considered by the investigator would affect the patient's participation in the study;
- •Psychiatric patients or other patients known or suspected to be unable to fully comply with the study protocol;
- •Pregnant or lactating women;
- •The researcher judged that the patients were not suitable for this study.
结局指标
主要结局
Progression-free survival
时间窗: Baseline up to data cut-off (up to approxiamately 2 years)
Progression-free survival was defined as the time from the data of ASCT until the date of the first documented day of disease progression or relapse, using Lugano criteria, or death from an cause, whichever occured first.
次要结局
- Overall survival(Baseline up to data cut-off (up to approxiamately 2 years))
- Complete remission rate(3 months after the transplantation)
- The time of hematopoietic reconstruction(2 months after the transplantation)
- Transplantation-related adverse reactions(Baseline up to data cut-off (up to approxiamately 4 years))
研究者
相似试验
尚未招募
2 期
Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCLDLBCL - Diffuse Large B Cell LymphomaPirtobrutinibNCT07744724Changzhou No.2 People's Hospital48
尚未招募
2 期
Pirtobrutinib+Sonrotoclax（PS) Regimen in the Treatment of B-Cell LymphomaDLBCL - Diffuse Large B Cell LymphomaCLL / SLLMZLRichter TransformationNCT07744750Changzhou No.2 People's Hospital40
尚未招募
不适用
A Real-World Study of Pirtobrutinib in cBTKi-Resistant/Intolerant Mature B-Cell LymphomaMature B-Cell LymphomaNCT07525817Ou Bai, MD/PHD40
招募中
3 期
A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with DLBCL-type Richter Transformation2024-513445-37-00University Of Cologne71
尚未招募
2 期
Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCLDLBCL - Diffuse Large B Cell LymphomaR-CHOP ChemotherapyPirtobrutinibNCT07744737Changzhou No.2 People's Hospital34